#None #Boston #PhaseV #Biopharma #AI/ML

PhaseV Transitions into a Leading Player in Biopharma AI/ML

In an impressive turn of events, PhaseV, a prominent figure in the AI/ML landscape for clinical development, has confirmed its remarkable growth trajectory as it closes out 2025. The company preliminarily reported nearly a fivefold increase in revenue and a notable rise in contract sizes, attributed to the increasing adoption of its complete platform subscriptions across its four integrated modules designed for comprehensive trial design and execution.

As a key partner to over 40 leading pharmaceutical sponsors and contract research organizations (CROs), including seven of the world’s most influential pharmaceutical companies, PhaseV is clearly capitalizing on the escalating demand for AI-driven solutions to enhance clinical development efficiency. Their growth surge was propelled by a $50 million Series A funding round led by venture capital heavyweights Accel and Insight Partners, alongside ongoing investment from existing supporters. This influx of capital positions PhaseV to amplify its influence and revolutionize the methodologies employed in clinical trial execution.

CEO and co-founder Raviv Pryluk, PhD, expressed optimism for the future, noting that while 2025 was characterized by initial AI pilots and promises, 2026 is poised for widespread deployment of these technologies, ensuring substantial impacts on clinical development. “Now is the time for pharma to fully embrace proven AI methodologies or risk being left behind,” he stated. This shift to embracing established AI practices is crucial for enhancing the accuracy, speed, and efficacy of clinical trials.

PhaseV’s proprietary platform continues to demonstrate a measurable return on investment for its sponsors. By adopting this technology, clients have witness trials conducted up to 40% faster and at 50% lower costs compared to traditional methods. The platform enables the execution of millions of virtual design simulations within minutes, effectively optimizing site selection and allowing for real-time monitoring of trials. PhaseV's efforts have significantly improved trial success probabilities by over 30%, translating to billions of dollars in previously unrecognized asset value for its partners.

Moreover, PhaseV has solidified its position in the industry by integrating over 2 million patient-level records into its advanced data lake, which now supports more than 20 predictive disease models across various therapeutic areas, such as oncology, immunology, neurology, gastrointestinal conditions, and rare diseases. This extensive data integration further enhances the predictive capabilities necessary for addressing complexities in clinical trials.

Throughout 2025, PhaseV garnered a substantial amount of industry recognition, including esteemed accolades from CB Insights’ Digital Health 50, TechCrunch’s AI Disruptors 60, and the Accel 2025 Europe AI 100 list. Additionally, they were honored as Analogities Solution of the Year by BioTech Breakthrough. The company also contributed to the academic community, publishing studies including one focused on Group Sequential Design in Statistics in Medicine, and actively participating in significant industry events such as Fierce Biotech Week and the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop.

Looking forward to 2026, PhaseV is set to deepen its collaborations with global sponsors while expanding its vertical AI platform to expedite drug pipelines, optimize study designs, and enhance patient outcomes across a spectrum of therapeutic domains. Executive team members will be in attendance at the upcoming JPM Healthcare Conference in San Francisco, as well as the Crohn's Colitis Congress and the Scope Summit—events crucial to advancing innovation in clinical trial management and operations.

About PhaseV

PhaseV specializes in developing cutting-edge AI/ML solutions designed to optimize clinical development processes. The firm partners with biopharmaceutical sponsors and CROs to design and execute adaptive, Bayesian, and fixed clinical trials efficiently. PhaseV’s platform is designed to analyze data and elucidate heterogeneous treatment effects, stratifying patients to inform future research and development directions. To date, the company has helped over 40 leading pharma and biotech sponsors achieve an impressive decrease in trial costs by 50%, reduced enrollment sizes and durations by 40%, and boosted trial success probabilities beyond 30%. Explore more about PhaseV at phasevtrials.com and follow their updates on LinkedIn.